<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38454468</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS).</ArticleTitle><Pagination><StartPage>172</StartPage><MedlinePgn>172</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-024-07982-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severely debilitating condition which markedly restricts activity and function of affected people. Since the beginning of the COVID-19 pandemic ME/CFS related to post-acute COVID-19 syndrome (PACS) can be diagnosed in a subset of patients presenting with persistent fatigue 6 months after a mostly mild SARS-CoV-2 infection by fulfillment of the Canadian Consensus Criteria (CCC 2003). Induction of autoimmunity after viral infection is a mechanism under intensive investigation. In patients with ME/CFS, autoantibodies against thyreoperoxidase (TPO), beta-adrenergic receptors (&#xdf;2AR), and muscarinic acetylcholine receptors (MAR) are frequently found, and there is evidence for effectiveness of immunomodulation with B cell depleting therapy, cyclophosphamide, or intravenous immunoglobulins (IVIG). Preliminary studies on the treatment of ME/CFS patients with immunoadsorption (IA), an apheresis that removes antibodies from plasma, suggest clinical improvement. However, evidence from placebo-controlled trials is currently missing.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this double-blinded, randomized, sham-controlled, exploratory trial the therapeutic effect of five cycles of IA every other day in patients with ME/CFS, including patients with post-acute COVID-19 chronic fatigue syndrome (PACS-CFS), will be evaluated using the validated Chalder Fatigue Scale, a patient-reported outcome measurement. A total of 66 patients will be randomized at a 2:1 ratio: 44 patients will receive IA (active treatment group) and 22 patients will receive a sham apheresis (control group). Moreover, safety, tolerability, and the effect of IA on patient-reported outcome parameters, biomarker-related objectives, cognitive outcome measurements, and physical parameters will be assessed. Patients will be hospitalized at the clinical site from day 1 to day 10 to receive five IA treatments and medical visits. Four follow-up visits (including two visits at site and two visits via telephone call) at month 1 (day 30), 2 (day 60), 4 (day 120), and 6 (day 180; EOS, end of study visit) will take place.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Although ME/CFS including PACS-CFS causes an immense individual, social, and economic burden, we lack efficient therapeutic options. The present study aims to investigate the efficacy of immunoadsorption and to contribute to the etiological understanding and establishment of diagnostic tools for ME/CFS.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Registration Number: NCT05710770 . Registered on 02 February 2023.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Pre&#xdf;ler</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Excellence Cluster NeuroCure, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Machule</LastName><ForeName>Marie-Luise</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-0969-4120</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ufer</LastName><ForeName>Friederike</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;nger</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lucie Yuanting</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchholz</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Research Organisation GmbH, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beraha</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Research Organisation GmbH, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Research Organisation GmbH, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metz</LastName><ForeName>Matthes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, GCP-Service International Ltd. &amp; Co. KG, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burock</LastName><ForeName>Susen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trial Office, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruckert</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Trial Office, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Christiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilck</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Medical Intensive Care Medicine, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental and Clinical Research Center (ECRC), a cooperation of Charit&#xe9; - Universit&#xe4;tsmedizin Berlin and Max Delbruck Center for Molecular Medicine (MDC), Berlin, 13125, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Delbr&#xfc;ck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Medical Intensive Care Medicine, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reshetnik</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Medical Intensive Care Medicine, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckardt</LastName><ForeName>Kai-Uwe</ForeName><Initials>KU</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Medical Intensive Care Medicine, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endres</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Excellence Cluster NeuroCure, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Stroke Research Berlin, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pr&#xfc;ss</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Experimental Neurology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin and Berlin Institute of Health, Charit&#xe9;platz 1, Berlin, 10117, Germany. harald.pruess@charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. harald.pruess@charite.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05710770</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">Immunoadsorption</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">PROMIS</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>0</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38454468</ArticleId><ArticleId IdType="pmc">PMC10919018</ArticleId><ArticleId IdType="doi">10.1186/s13063-024-07982-5</ArticleId><ArticleId IdType="pii">10.1186/s13063-024-07982-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) J Transl Med. 2020;18(1):100. doi: 10.1186/s12967-020-02269-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02269-0</ArticleId><ArticleId IdType="pmc">PMC7038594</ArticleId><ArticleId IdType="pubmed">32093722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis GSA, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. medRxiv; 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270(4):327&#x2013;338. doi: 10.1111/j.1365-2796.2011.02428.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Zoller T, Steinbeis F, Haffke M, Rudolf G, Heidecker B, Volk HD, Co S, Paul F, Bellmann-Strobl J, Scheibenbogen C. Chronic COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) following the first pandemic wave in Germany- a first analysis of a prospective observational study. medRxiv; 2021.</Citation></Reference><Reference><Citation>Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun. 2016;52:32&#x2013;39. doi: 10.1016/j.bbi.2015.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.09.013</ArticleId><ArticleId IdType="pubmed">26399744</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge O, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, et al. B-lymphocyte depletion in myalgic encephalopathy/ chronic fatigue syndrome. an open-label phase II study with rituximab maintenance treatment. PLoS One. 2015;10(7):e0129898. doi: 10.1371/journal.pone.0129898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129898</ArticleId><ArticleId IdType="pmc">PMC4488509</ArticleId><ArticleId IdType="pubmed">26132314</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekeland IG, Fossa A, Lande A, Ktoridou-Valen I, Sorland K, Holsen M, et al. Intravenous cyclophosphamide in myalgic encephalomyelitis/chronic fatigue syndrome. An open-label phase II study. Front Med (Lausanne). 2020;7:162. doi: 10.3389/fmed.2020.00162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00162</ArticleId><ArticleId IdType="pmc">PMC7201056</ArticleId><ArticleId IdType="pubmed">32411717</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C, Sotzny F, Hartwig J, Bauer S, Freitag H, Wittke K, et al. Tolerability and efficacy of s.c. IgG self-treatment in ME/CFS patients with IgG/IgG subclass deficiency: a proof-of-concept study. J Clin Med. 2021;10(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8198960</ArticleId><ArticleId IdType="pubmed">34072494</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlie H, Speight N. Back to the future? Immunoglobulin therapy for myalgic encephalomyelitis/chronic fatigue syndrome. Healthcare (Basel). 2021;9(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8623195</ArticleId><ArticleId IdType="pubmed">34828592</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415&#x2013;419. doi: 10.1016/j.bbi.2020.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.12.022</ArticleId><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein SR, Voit-Bak K, Donate T, Rodionov RN, Gainetdinov RR, Tselmin S, et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: is there a role for extracorporeal apheresis? Mol Psychiatry. 2022;27(1):34&#x2013;37. doi: 10.1038/s41380-021-01148-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01148-4</ArticleId><ArticleId IdType="pmc">PMC8209771</ArticleId><ArticleId IdType="pubmed">34140635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Delamarre L, Gollion C, Grouteau G, Rousset D, Jimena G, Roustan J, et al. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J Neurol Neurosurg Psychiatry. 2020;91(9):1004&#x2013;1006. doi: 10.1136/jnnp-2020-323678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323678</ArticleId><ArticleId IdType="pmc">PMC7476305</ArticleId><ArticleId IdType="pubmed">32651243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder J, Feresiadou A, Fallmar D, Frithiof R, Virhammar J, Rasmusson A, et al. autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with COVID-19. Am J Psychiatry. 2021;178(6):485&#x2013;489. doi: 10.1176/appi.ajp.2020.20081236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2020.20081236</ArticleId><ArticleId IdType="pubmed">34154381</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilmot A, Maldonado Slootjes S, Sellimi A, Bronchain M, Hanseeuw B, Belkhir L, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol. 2021;268(3):751&#x2013;757. doi: 10.1007/s00415-020-10108-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10108-x</ArticleId><ArticleId IdType="pmc">PMC7391231</ArticleId><ArticleId IdType="pubmed">32734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. Immunoadsorption to remove ss2 adrenergic receptor antibodies in chronic fatigue syndrome CFS/ME. PLoS One. 2018;13(3):e0193672. doi: 10.1371/journal.pone.0193672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193672</ArticleId><ArticleId IdType="pmc">PMC5854315</ArticleId><ArticleId IdType="pubmed">29543914</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolle M, Freitag H, Antelmann M, Hartwig J, Schuchardt M, van der Giet M, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: efficacy of repeat immunoadsorption. J Clin Med. 2020;9(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7465279</ArticleId><ArticleId IdType="pubmed">32751659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Fillies F, Dreyhaupt J, Senel M, Tumani H. Safety and tolerability of plasma exchange and immunoadsorption in neuroinflammatory diseases. J Clin Med. 2020;9(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565027</ArticleId><ArticleId IdType="pubmed">32899499</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs K, Rummler S, Ries W, Helmschrott M, Selbach J, Ernst F, et al. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. Ther Apher Dial. 2022;26(1):229&#x2013;241. doi: 10.1111/1744-9987.13663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1744-9987.13663</ArticleId><ArticleId IdType="pmc">PMC9291474</ArticleId><ArticleId IdType="pubmed">33914397</ArticleId></ArticleIdList></Reference><Reference><Citation>Boedecker SC, Luessi F, Engel S, Kraus D, Klimpke P, Holtz S, et al. Immunoadsorption and plasma exchange-efficient treatment options for neurological autoimmune diseases. J Clin Apher. 2022;37(1):70&#x2013;81. doi: 10.1002/jca.21953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21953</ArticleId><ArticleId IdType="pubmed">34904748</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella M, Chalder T. Measuring fatigue in clinical and community settings. J Psychosom Res. 2010;69(1):17&#x2013;22. doi: 10.1016/j.jpsychores.2009.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2009.10.007</ArticleId><ArticleId IdType="pubmed">20630259</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. Health Technol Assess. 2006;10(37) iii-iv, ix-x, 1-121.</Citation><ArticleIdList><ArticleId IdType="pubmed">17014748</ArticleId></ArticleIdList></Reference><Reference><Citation>Smakowski A, Adamson J, Turner T, Chalder T. Graded exercise therapy for patients with chronic fatigue syndrome in secondary care - a benchmarking study. Disabil Rehabil. 2021;1-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34498994</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley E, Collin SM, White PD, Rimes K, Sterne JAC, May MT. Treatment outcome in adults with chronic fatigue syndrome: a prospective study in England based on the CFS/ME National Outcomes Database. QJM. 2020;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665909</ArticleId><ArticleId IdType="pubmed">23538643</ArticleId></ArticleIdList></Reference><Reference><Citation>Wearden AJ, Emsley R. Mediators of the effects on fatigue of pragmatic rehabilitation for chronic fatigue syndrome. J Consult Clin Psychol. 2013;81(5):831&#x2013;838. doi: 10.1037/a0033561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0033561</ArticleId><ArticleId IdType="pubmed">23796316</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147&#x2013;153. doi: 10.1016/0022-3999(93)90081-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3999(93)90081-P</ArticleId><ArticleId IdType="pubmed">8463991</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Taft C, Lundgren-Nilsson A, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16:62. doi: 10.1186/s12874-016-0167-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0167-6</ArticleId><ArticleId IdType="pmc">PMC4937582</ArticleId><ArticleId IdType="pubmed">27387456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet. 1999;353(9151):455&#x2013;458. doi: 10.1016/S0140-6736(98)04074-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(98)04074-4</ArticleId><ArticleId IdType="pubmed">9989716</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post COVID syndrome correlate with symptom severity. Front Immunol. 2022;13:981532. doi: 10.3389/fimmu.2022.981532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.981532</ArticleId><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Boesl F, Goereci Y, Gerhard A, Schweitzer F, Schroeder M, et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav Immun. 2023;109:139&#x2013;143. doi: 10.1016/j.bbi.2023.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC9841734</ArticleId><ArticleId IdType="pubmed">36657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022;13(1):5104. doi: 10.1038/s41467-022-32507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Boada M, Lopez OL, Olazaran J, Nunez L, Pfeffer M, Paricio M, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer&#x2019;s disease: primary results of the AMBAR Study. Alzheimers Dement. 2020;16(10):1412&#x2013;1425. doi: 10.1002/alz.12137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12137</ArticleId><ArticleId IdType="pmc">PMC7984263</ArticleId><ArticleId IdType="pubmed">32715623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>